Comparison of 5‐Fluorouracil/Leucovorin and Capecitabine as Adjuvant Therapies in Biliary Tract Cancer
Journal of Gastroenterology and Hepatology · 2025
DOI: 10.1111/jgh.17044 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Tae Seung Lee und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seou…. Hauptthemen laut MEDLINE: Capecitabine, Fluorouracil, Leucovorin, Biliary Tract Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
The prognosis of biliary tract cancer (BTC) is poor, and recurrence rates remain high even after curative resection. This study aimed to compare the efficacy and safety of capecitabine and 5‐fluorouracil/leucovorin (FL) as adjuvant treatments following curative resection in patients with BTC.
Methods
We retrospectively reviewed the medical records of patients with BTC (including gallbladder and extrahepatic and intrahepatic bile duct cancers) who underwent curative surgical resection and adjuvant chemotherapy between 2011 and 2023. The recurrence‐free survival, overall survival, and adverse events were investigated between the two groups.
Results
Of the 263 patients, 85 and 178 received capecitabine and FL, respectively. The recurrence‐free survival and overall survival did not show statistically significant differences between the capecitabine and FL groups. After propensity score matching, the capecitabine group showed significantly longer overall survival (median, NA [52 − NA] vs. 43 months [32 − NA], p = 0.032). Although severe adverse events did not differ between both groups (29.4% vs. 20.2%, p = 0.135), overall adverse events, including anemia, thrombocytopenia, hand–foot syndrome, and skin color change, were significantly more frequent in the capecitabine group (90.6% vs. 57.9%, p < 0.001). After propensity score matching, severe adverse events (30.3% vs. 14.5%, p = 0.032) and overall adverse events (90.8% vs. 65.8%, p < 0.001) were significantly more frequent in the capecitabine group.
Conclusion
In patients with curatively resected BTC, capecitabine demonstrated superior efficacy in prolonging overall survival, whereas FL had a more favorable safety profile with fewer adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Internal Medicine, College of Medicine, Catholic University of Korea, Seoul, South Korea.
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
- Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Sang Hyub Lee, Ji Kon Ryu, Woo Hyun Paik
Zitieren
APA
Lee, T. S., Choi, Y. H., Kim, J. Y., Lee, M. H., Paik, K. H., Cho, I. R., Kwon, W. I., Lee, S. H., Lee, I. S., Lee, M. A., Jang, J. Y., Ryu, J. K., Kim, Y. T., & Paik, W. H. (2025). Comparison of 5‐Fluorouracil/Leucovorin and Capecitabine as Adjuvant Therapies in Biliary Tract Cancer. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.17044
Vancouver
Lee TS, Choi YH, Kim JY, Lee MH, Paik KH, Cho IR, et al. Comparison of 5‐Fluorouracil/Leucovorin and Capecitabine as Adjuvant Therapies in Biliary Tract Cancer. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.17044
BibTeX
@article{Lee2025,
author = {Lee, Tae Seung and Choi, Young Hoon and Kim, Jun Yeol and Lee, Myeong Hwan and Paik, Kyu-Hyun and Cho, In Rae and Kwon, Woo Il and Lee, Sang Hyub and Lee, In Seok and Lee, Myung Ah and Jang, Jin-Young and Ryu, Ji Kon and Kim, Yong-Tae and Paik, Woo Hyun},
title = {Comparison of 5‐Fluorouracil/Leucovorin and Capecitabine as Adjuvant Therapies in Biliary Tract Cancer},
journal = {Journal of Gastroenterology and Hepatology},
year = {2025},
doi = {10.1111/jgh.17044}
}
EUVIMED